Keeping pressure on Amgen, Mirati draws mixed reviews on latest cut of KRAS data - Endpoints News

As the close runner-up to Amgen’s Lumakras in the KRAS race, any data cut from Mirati’s adagrasib continues to draw scrutiny from analysts. And the latest batch of numbers from ASCO is a decidedly mixed bag. While a quick comparison suggests that adagrasib sp…

As Neulasta sales slip, Amgen has yet another biosimilar to look out for: Amneal Pharmaceuticals and Kashiv Biosciences’ Flynetra. Flynetra became the fifth approved biosimilar to Neulasta on Friday… [+405 chars]

full article...